SAS Output

26-MAY-2017 18:11

OPEN STUDIES IRB REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Disease
Site
Study Study Name Open Date Number of
Active
Institutions
Number of
Current
IRBs
 
BREAST S1007 Breast,Adj,N1,Endocrine+/-Chemo 15-JAN-11 430 214
  S1207 Brst,Adj,Endocrine+/-Everolimus 03-SEP-13 482 246
  S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 07-JUL-16 248 119
  S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 15-NOV-16 314 126
  A011106 Breast, Neoadj, ALTERNATE study 15-FEB-14 260 121
  A011203 Breast, Adv, Tam vs Endoxifen 27-JAN-15 240 90
  A011401 Breast, adj, Stage II/III HER2-, weight loss 29-AUG-16 246 126
  B55 Brst, Adj Olaparib for BRCA,TNBC 03-JUL-14 407 185
  E1Z11 Brst,Genetic Predictors of AIMSS 10-MAY-13 256 92
  E2112 Brst,Adv,Exemestane+/-Entinostat 02-JAN-14 297 163
  NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo 22-JAN-15 441 216
 
Breast A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 08-DEC-16 0 164
 
CCD S1415CD TrACER CSF Standing Order Intervention for FN 01-SEP-16 52 65
  S1417CD Colorectal, Cost Cohort Study 13-MAY-16 207 56
  A011104 Preoperative Breast MRI 21-FEB-14 175 63
 
ERLYTX S1609 Rare Tumor, Comb Nivo/Ipi 13-JAN-17 309 120
  A071102 GBM, adj TMZ +/- Veliparib 19-SEP-14 356 157
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 06-AUG-15 234 99
  ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) 16-MAY-14 220 113
  EAY131 MATCH 12-AUG-15 435 226
 
GI S1505 Panc,Resect, Perioperative Chemo 12-OCT-15 291 134
  S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 01-SEP-16 275 117
  A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT 01-DEC-16 0 2
  E7208 CRC,Adv, Irino/Cet+/-Ramucirumab 20-FEB-14 199 86
  EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo 29-JAN-16 0 16
  EA2142 GI NEC, Adv G3, EP vs TMZ + CAP 06-NOV-15 182 68
  N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX 13-JAN-12 0 160
  NRGGI002 Rectal, Ph II, Sensitization using TNT 12-OCT-16 191 98
  R0848 Panc, Adj, Erlotinib v ChemoRT 01-MAR-14 0 148
 
GU S1216 Pros Adv, ADT +/- TAK-700 or Bic 01-MAR-13 143 154
  S1314 Blad, COXEN Neoadj. Chemo + Cyst 11-JUL-14 232 112
  S1500 pRCC,Adv, Sunitinib vs MET inhib 05-APR-16 191 82
  S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 07-FEB-17 74 37
  S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab 07-FEB-17 93 42
  A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 01-JUL-15 6 5
  E2810 Renal, Pazopanib vs Placebo 17-APR-12 173 83
  EA8141 UTUC, HG, Chemo then Surg 27-JAN-15 159 75
  R0924 Pros, NADT+WPRT vs. NADT+P&SV RT 07-JUL-11 0 153
 
LEUK S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP 01-APR-14 5 6
  S1318 ALL, Age 65+, Ph±, Blinatumomab 12-JAN-15 174 68
  S0919 Rel AML: Pravastatin+Ida+Ara-C 15-AUG-09 86 29
  E1910 BCR-ABL-neg, B ALL, Blinatumomab 23-DEC-13 157 80
  E2906 AML, Age 60+, Clo vs Dauno+Cy 24-FEB-11 157 81
  NHLBIMDS LEUK, National MDS Study 05-APR-16 48 17
 
LUNG S1400 SCCA,Adv, Biomarker Master 15-JUN-14 439 217
  S1400G HRRD: Talazoparib (BMN 673) 07-FEB-17 431 207
  S1400I Non-Match: Nivo + Ipi vs Nivo 18-DEC-15 439 216
  S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab 25-MAR-15 223 87
  S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel 18-JUL-16 164 78
  8811 NSCLC, Stage III,ChemoRT+ABT-888 02-JAN-13 108 36
  A081105 ALCHEMIST1, EGFR mut, Erlotinib 02-JAN-14 0 246
  A151216 ALCHEMIST0 - screening 06-FEB-14 459 247
  C140503 NSCL, Lobect v Sublobar resect 09-JUL-07 104 56
  C30610 SCLC, Thoracic RT 21-MAR-08 240 111
  E4512 ALCHEMIST2, ALK mut, Crizotinib 18-AUG-14 463 244
  EA5142 ALCHEMIST3, Non-match, Nivolumab 16-MAY-16 433 224
  NRGCC003 SCLC, PCI or HA-PCI 07-DEC-15 318 128
  R1306 NSCLC,Adv,ALK/EGFR,TargetAgents 04-NOV-13 144 67
 
LYMPH A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo 15-JUL-16 104 43
 
MELAN S1320 Adv, BRAF mut, Inter v Contin 22-JUL-14 242 100
  S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 15-OCT-15 416 174
  S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) 20-OCT-16 49 20
  EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 15-DEC-15 340 137
  EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim 01-MAR-16 263 102
 
MMYEL E1A11 MM, frontline, BLD vs CLD 22-NOV-13 299 125
  E3A06 AMM, Lenalidomide vs Observation 08-NOV-10 275 123
 
OTHER A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo 02-SEP-14 39 22
  A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II 26-JAN-15 176 65
  A091305 HN, Adv, Thyroid PPAR agonist + Chemo 01-SEP-14 90 28
  A091401 Sarc, 18-JUN-15 195 76
  A091404 HN, AR+, Enzalutamide 25-SEP-15 23 7
  AOST1521 Osteo CDX-011 in Rec/Ref Dz,Ph 2 02-JUL-15 76 44
  E3311 Oroph,Srg + Low or Std IMRT 01-MAR-14 175 65
  EAQ152 Communication & education in tumor profiling 26-SEP-16 165 76
  G0281 Ovar, Recur/prog LG, IC chemo vs trametinib 27-FEB-14 0 15
  NRGBN001 HN, novel vs. std chemoradiation + chemo 28-AUG-15 0 92
  NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo 04-FEB-16 338 147
  NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care 06-FEB-16 123 50
  NRGHN001 Nasopharyngeal , Indiviual Tx EBV 21-APR-14 202 86
  NRGHN002 HN, Adv, Orophyx RT vs RT+ Chemo 27-OCT-14 284 102
  R0724 Cervical, Chem+RT +/- Adj. Chemo 15-JAN-14 232 95
  R0920 HN, Adv, Postop IMRT ± Cetuximab 24-DEC-13 384 182
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 276 117
 
PREV S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac 01-MAR-13 305 110
  A211102 Breast, Atypia via RPFNA, Metformin v Placebo 01-FEB-15 29 7
  A211201 Breast Density, MA.32 companion 22-AUG-12 54 13
 
SURV S1316 Compar. Effectiv. Trial for MBO 09-MAR-15 10 16
  E1Q11 EROS: Reproductive Health in Cancer Survivors 30-SEP-15 0 35
 
SXQOL A221101 Glioma, Nuvigil/Placebo Fatigue 03-JUN-13 184 80
  A221102 Brst,AI Arthralgia,Testosterone 07-SEP-12 0 67